- Chief Executive Officer：
- Chizuko Koseki
Oligonucleotide-based drug discovery platform to revolutionize expensive healthcare economy by discovering low cost, highly effective, and safe medicines.
TAGCyx focuses on creating novel nucleic acid-based drugs for pharmaceutical applications through its revolutionary nucleic acid-based drug discovery platform, “Xenoligo system”. The platform enables the screening of drug candidates from large oligonucleotide libraries containing highly functional non-natural bases and their stability optimization. Xenoligo molecules possess high selectivity and affinity against their targets which provide significant advantages compared to conventional small-molecule and protein therapeutics.
With the vision to commercialize “Artificial base-pairing technology” and its application in a wide range of Life Science fields, Dr.Hirao Ichiro and others co-founded TagCyx in 2007. From 2016, TAGCyx is targeting drug discovery and development as their main focus.
Nucleic acid drugs can be created with unprecedented efficacy using the Xenoligo™ platform which possesses high affinity and selectivity for target substances.
UTEC’s value add
UTEC accelerates TAGCyx development into a global market leader in the field of drug discovery and pharmaceuticals through our network: assembling a strong team of high performing individuals and connections to the industry.
Generation of Xenoligo molecules by SELEX